Hy BioPharma - Commercializing an Advanced Drug Technology

Technology

Hypericin is a late-stage drug development opportunity that provides a wide range of therapeutic benefits by regulating cancer cell replication through inhibition of cell signaling pathways.

Hypericin targets Heat-Shock Protein 90 (HSP 90) , which controls multiple cell signaling pathways thus ameliorating a broad range of pathologies.
Hypericin inhibits angiogenesis, thereby blocking the formation of new blood vessels, thus preventing the development of tumor metastases.
Hypericin represents a novel anti-cancer, anti-inflammatory and immuno-regulatory agent.
Hypericin has shown efficacy against malignant brain tumors (gliomas), cutaneouf T cell lymphoma (CTCL), and psoriasis in clinical trials.

Hy BioPharma has developed a range of novel applications addressing key pathological conditions. Clinical data confirm safety and efficacy in patients.

HBP-412 is a second generation compound in preclinical research that has shown promise in the treatment of Multiple Sclerosis.